YOOR BRIAN B 4
4 · ABBOTT LABORATORIES · Filed Jan 30, 2020
Insider Transaction Report
Form 4
YOOR BRIAN B
Senior Vice President and CFO
Transactions
- Sale
Common shares without par value
2020-01-28$89.73/sh−509,850$45,747,209→ 114,381 total - Exercise/Conversion
Option (right to buy)
2020-01-28−41,229→ 0 totalExercise: $47.00From: 2018-02-20Exp: 2025-02-19→ Common shares (41,229 underlying) - Exercise/Conversion
Option (right to buy)
2020-01-28−81,709→ 0 totalExercise: $48.90From: 2018-06-01Exp: 2025-05-31→ Common shares (81,709 underlying) - Exercise/Conversion
Option (right to buy)
2020-01-28−213,470→ 0 totalExercise: $38.40From: 2019-02-19Exp: 2026-02-18→ Common shares (213,470 underlying) - Exercise/Conversion
Option (right to buy)
2020-01-28−91,121→ 45,561 totalExercise: $44.40From: 2019-02-17Exp: 2027-02-16→ Common shares (91,121 underlying) - Exercise/Conversion
Option (right to buy)
2020-01-28−82,321→ 164,642 totalExercise: $59.94From: 2019-02-16Exp: 2028-02-15→ Common shares (82,321 underlying) - Exercise/Conversion
Common shares without par value
2020-01-28$47.00/sh+41,229$1,937,763→ 155,610 total - Exercise/Conversion
Common shares without par value
2020-01-28$44.40/sh+91,121$4,045,772→ 541,910 total - Exercise/Conversion
Common shares without par value
2020-01-28$48.90/sh+81,709$3,995,570→ 237,319 total - Exercise/Conversion
Common shares without par value
2020-01-28$38.40/sh+213,470$8,197,248→ 450,789 total - Exercise/Conversion
Common shares without par value
2020-01-28$59.94/sh+82,321$4,934,321→ 624,231 total
Holdings
- 2,239(indirect: By Trust)
Common shares without par value
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.57 to $89.87, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]Balance in the Abbott Laboratories Stock Retirement Trust as of January 28, 2020.
- [F3]Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
- [F4]Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.